Article
A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.
Clinical chemistry and laboratory medicine - 1 Feb 2011
Li Guoqiang, Luo Xiaodi, He Jiaying, Zhu Zeyao, Yu Gang, Qin Huijuan, Zeng Tao, Liu Zhiming, Wu Shiyang, Xu Jiasen, Ren-Heidenreich Lifen
Abstract excerpt
BACKGROUND: DNA somatic mutations of EGFR, KRAS, BRAF and PIK3CA in the epidermal growth factor receptor (EGFR) signaling pathway play critical roles in the response or resistance of tumors to targeted therapy with tyrosine kinase inhibitors (EGFR-TKIs). To provide a high-throughput (HTP) clinical testing service for detecting these mutations, we developed a novel platform, SurPlex®-xTAG70plex-EGFR liquidchip....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.